학술논문
Prognostic significance of micronest in cancer stroma in resected lung squamous cell carcinoma.
Document Type
Academic Journal
Author
Kaminuma Y; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: kouhan.work@gmail.com.; Nakai T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: tonakai@east.ncc.go.jp.; Aokage K; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: kaokage@east.ncc.go.jp.; Taki T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: tetaki@east.ncc.go.jp.; Miyoshi T; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: tmiyoshi@east.ncc.go.jp.; Tane K; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: ktane@east.ncc.go.jp.; Samejima J; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: jsamejim@east.ncc.go.jp.; Miyazaki S; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: samiyaza@east.ncc.go.jp.; Sakamoto N; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. Electronic address: naosakam@east.ncc.go.jp.; Sakashita S; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. Electronic address: ssakashi@east.ncc.go.jp.; Kojima M; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. Electronic address: mokojima@east.ncc.go.jp.; Watanabe R; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: reikwata@east.ncc.go.jp.; Tsuboi M; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address: mtsuboi@east.ncc.go.jp.; Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan; Division of Innovative Pathology and Laboratory Medicine, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. Electronic address: gishii@east.ncc.go.jp.
Source
Publisher: W B Saunders Country of Publication: United States NLM ID: 9421547 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8392 (Electronic) Linking ISSN: 00468177 NLM ISO Abbreviation: Hum Pathol Subsets: MEDLINE
Subject
Language
English
Abstract
Tumor budding in the cancer stroma has been reported to be a prognostic factor in non-small cell lung cancer. Micronest in cancer stroma (MICS) is often observed as a formation that is larger and more conspicuous than budding, but its clinicopathologic significance is unclear. In this study, we aimed to examine the clinicopathological significance of MICS in lung squamous cell carcinoma (LSqCC). A total of 198 consecutive patients with pathologically diagnosed LSqCC (anyT N0-1M0) were enrolled in this study. MICS were defined as those that met the following criteria: (1) consisting of 5-200 tumor cells or less than 200 μm in diameter and (2) more than 200 μm away from the adjacent main lesion. The prognostic impact of the presence or absence of MICS and the characteristics of MICS-forming cancer cells were evaluated by immunohistochemistry (IHC). MICS was observed in 57 patients (28.8%), and overall survival (OS) and recurrence-free survival (RFS) were significantly shorter in the MICS-positive group (OS: 44.4% vs. 84.4%, p<0.001; RFS: 30.0% vs. 82.6%, p<0.001). Univariate and multivariate analyses revealed that the presence of MICS was an independent poor prognostic factor for OS (hazard ratio [HR] 3.54, p<0.001) and RFS (HR 4.99, p<0.001). Immunohistochemistry showed that the expression levels of the cell-cell adhesion molecule E-cadherin and hypoxia-induced protein GLUT-1 were significantly decreased in cancer cells forming MICS lesions compared to the tumor component excluding MICS within the same tumor (non-MICS lesions). Our data show that MICS is a distinct morphological feature with important biological and prognostic significance.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest related to the present study.
(Copyright © 2024. Published by Elsevier Inc.)
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest related to the present study.
(Copyright © 2024. Published by Elsevier Inc.)